← All trials
NCT05442983
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 12, 2022
- Primary completion
- Sep 7, 2022
- Completion date
- Oct 8, 2022
- First posted
- Jul 5, 2022
- Last posted
- Oct 13, 2022
- Enrollment
- 75
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- TrippBio, Inc.Lead sponsor
- TrippBio, Inc.Study director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.